Page 353 - Read Online

Page 18 of 20 Smigiel et al. J Cancer Metastasis Treat 2019;5:47 I http://dx.doi.org/10.20517/2394-4722.2019.26

Radiat Res 2016;186:327-32.
185. Alotaibi M, Sharma K, Saleh T, Povirk LF, Hendrickson EA, et al. Radiosensitization by PARP inhibition in DNA repair proficient and
deficient tumor cells: proliferative recovery in senescent cells. Radiat Res 2016;185:229-45.
186. Ali M, Kamjoo M, Thomas HD, Kyle S, Pavlovska I, et al. The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity
but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice. Mol Cancer Ther
2011;10:2320-9.
187. Shelton JW, Waxweiler TV, Landry J, Gao H, Xu Y, et al. In vitro and in vivo enhancement of chemoradiation using the oral PARP
inhibitor ABT-888 in colorectal cancer cells. Int J Radiat Oncol Biol Phys 2013;86:469-76.
188. Tlsty TD, Crawford YG, Holst CR, Fordyce CA, Zhang J, et al. Genetic and epigenetic changes in mammary epithelial cells may mimic
early events in carcinogenesis. J Mammary Gland Biol Neoplasia 2004;9:263-74.
189. Jiang Z, Jones R, Liu JC, Deng T, Robinson T, et al. RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell Cycle
2011;10:1563-70.
190. Bendris N, Cheung CT, Leong HS, Lewis JD, Chambers AF, et al. Cyclin A2, a novel regulator of EMT. Cell Mol Life Sci 2014;71:4881-
94.
191. Emadi Baygi M, Soheili ZS, Schmitz I, Sameie S, Schulz WA. Snail regulates cell survival and inhibits cellular senescence in human
metastatic prostate cancer cell lines. Cell Biol Toxicol 2010;26:553-67.
192. Wang T, Li Y, Wang W, Tuerhanjiang A, Wu Z, et al. Twist2, the key Twist isoform related to prognosis, promotes invasion of cervical
cancer by inducing epithelial-mesenchymal transition and blocking senescence. Hum Pathol 2014;45:1839-46.
193. Smit MA, Peeper DS. Deregulating EMT and senescence: double impact by a single twist. Cancer Cell 2008;14:5-7.
194. Ansieau S, Courtois-Cox S, Morel AP, Puisieux A. Failsafe program escape and EMT: a deleterious partnership. Semin Cancer Biol
2011;21:392-6.
195. de Carne Trecesson S, Guillemin Y, Belanger A, Bernard AC, Preisser L, et al. Escape from p21-mediated oncogene-induced senescence
leads to cell dedifferentiation and dependence on anti-apoptotic Bcl-xL and MCL1 proteins. J Biol Chem 2011;286:12825-38.
196. Weinberg RA. Twisted epithelial-mesenchymal transition blocks senescence. Nat Cell Biol 2008;10:1021-3.
197. Salmina K, Jankevics E, Huna A, Perminov D, Radovica I, et al. Up-regulation of the embryonic self-renewal network through reversible
polyploidy in irradiated p53-mutant tumour cells. Exp Cell Res 2010;316:2099-112.
198. Chitikova ZV, Gordeev SA, Bykova TV, Zubova SG, Pospelov VA, et al. Sustained activation of DNA damage response in irradiated
apoptosis-resistant cells induces reversible senescence associated with mTOR downregulation and expression of stem cell markers. Cell
Cycle 2014;13:1424-39.
199. Le Duff M, Gouju J, Jonchere B, Guillon J, Toutain B, et al. Regulation of senescence escape by the cdk4-EZH2-AP2M1 pathway in
response to chemotherapy. Cell Death Dis 2018;9:199.
200. Milanovic M, Fan DNY, Belenki D, Dabritz JHM, Zhao Z, et al. Senescence-associated reprogramming promotes cancer stemness.
Nature 2018;553:96-100.
201. Barreto-Andrade JC, Efimova EV, Mauceri HJ, Beckett MA, Sutton HG, et al. Response of human prostate cancer cells and tumors to
combining PARP inhibition with ionizing radiation. Mol Cancer Ther 2011;10:1185-93.
202. Wu PC, Wang Q, Grobman L, Chu E, Wu DY. Accelerated cellular senescence in solid tumor therapy. Exp Oncol 2012;34:298-305.
203. Mathiesen RR, Borgen E, Renolen A, Lokkevik E, Nesland JM, et al. Persistence of disseminated tumor cells after neoadjuvant
treatment for locally advanced breast cancer predicts poor survival. Breast Cancer Res 2012;14:R117.
204. Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, et al. Systemic spread is an early step in breast cancer. Cancer Cell
2008;13:58-68.
205. Heitzer E, Perakis S, Geigl JB, Speicher MR. The potential of liquid biopsies for the early detection of cancer. NPJ Precis Oncol
2017;1:36.
206. Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, et al. Biological and molecular heterogeneity of breast cancers correlates with
their cancer stem cell content. Cell 2010;140:62-73.
207. Doherty MR, Smigiel JM, Junk DJ, Jackson MW. Cancer Stem Cell Plasticity Drives Therapeutic Resistance. Cancers (Basel) 2016;8.
208. Pastushenko I, Brisebarre A, Sifrim A, Fioramonti M, Revenco T, et al. Identification of the tumour transition states occurring during
EMT. Nature 2018;556:463-8.
209. Goldman A, Majumder B, Dhawan A, Ravi S, Goldman D, et al. Temporally sequenced anticancer drugs overcome adaptive resistance
by targeting a vulnerable chemotherapy-induced phenotypic transition. Nat Commun 2015;6:6139.
210. Biddle A, Liang X, Gammon L, Fazil B, Harper LJ, et al. Cancer stem cells in squamous cell carcinoma switch between two distinct
phenotypes that are preferentially migratory or proliferative. Cancer Res 2011;71:5317-26.
211. Li QQ, Xu JD, Wang WJ, Cao XX, Chen Q, et al. Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to
multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res 2009;15:2657-65.
212. Sun L, Yao Y, Liu B, Lin Z, Lin L, et al. MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in
human tongue cancer cells by targeting BMI1. Oncogene 2012;31:432-45.
213. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell
subpopulations. Cell 2010;141:69-80.
214. Pisco AO, Huang S. Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse: 'What does not kill me
strengthens me'. Br J Cancer 2015;112:1725-32.
215. Cazet AS, Hui MN, Elsworth BL, Wu SZ, Roden D, et al. Targeting stromal remodeling and cancer stem cell plasticity overcomes